SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 4.4% – Should You Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s stock price traded down 4.4% on Tuesday . The stock traded as low as $3.68 and last traded at $3.68. 50,630 shares were traded during mid-day trading, a decline of 44% from the average session volume of 89,960 shares. The stock had previously closed at $3.85.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

SOPHiA GENETICS Stock Down 4.4 %

The firm has a market cap of $240.60 million, a PE ratio of -3.38 and a beta of 1.03. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The stock has a 50 day simple moving average of $3.39 and a 200-day simple moving average of $3.55.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC purchased a new stake in SOPHiA GENETICS in the 4th quarter worth $70,000. Green Alpha Advisors LLC lifted its stake in shares of SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after purchasing an additional 25,686 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after buying an additional 86,764 shares during the period. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.